{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:28:00Z","timestamp":1792211280166,"version":"4.4.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Abdom Radiol"],"DOI":"10.1007\/s00261-025-04856-5","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T06:50:01Z","timestamp":1742194201000},"page":"4110-4124","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Intrahepatic cholangiocarcinoma: role of imaging as a critical component for multi-disciplinary treatment approach"],"prefix":"10.1007","volume":"50","author":[{"given":"Betzaira G.","family":"Childers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason W.","family":"Denbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Hoffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetiana","family":"Glushko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliya","family":"Qayyum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Anaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"issue":"9935","key":"4856_CR1","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","volume":"383","author":"N Razumilava","year":"2014","unstructured":"Razumilava, N, Gores, GJ. (2014) Cholangiocarcinoma. Lancet. 383(9935):2168\u201379.","journal-title":"Cholangiocarcinoma. Lancet"},{"issue":"2","key":"4856_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.suronc.2016.12.009","volume":"26","author":"AA Rahnemai-Azar","year":"2017","unstructured":"Rahnemai-Azar, AA, Weisbrod, A, Dillhoff, M, Schmidt, C, Pawlik, TM. (2017) Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis. Surg Oncol. 26(2):125\u201337.","journal-title":"Surg Oncol."},{"key":"4856_CR3","doi-asserted-by":"crossref","unstructured":"Albrecht, T, Rossberg, A, Rose, F, Breuhahn, K, Baumann, EM, Toth, M, et al. (2024) Combined analysis of albumin in situ hybridisation and C reactive protein immunohistochemistry for the diagnosis of intrahepatic cholangiocarcinoma: towards a molecular classification paradigm. J Clin Pathol.","DOI":"10.1136\/jcp-2024-209429"},{"issue":"9","key":"4856_CR4","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales, JM, Marin, JJG, Lamarca, A, Rodrigues, PM, Khan, SA, Roberts, LR, et al. (2020) Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 17(9):557\u201388.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"8","key":"4856_CR5","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/modpathol.2013.241","volume":"27","author":"JY Liau","year":"2014","unstructured":"Liau, JY, Tsai, JH, Yuan, RH, Chang, CN, Lee, HJ, Jeng, YM. (2014) Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features. Mod Pathol. 27(8):1163\u201373.","journal-title":"Mod Pathol"},{"issue":"1","key":"4856_CR6","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/hep.24351","volume":"54","author":"GL Tyson","year":"2011","unstructured":"Tyson, GL, El-Serag, HB. (2011) Risk factors for cholangiocarcinoma. Hepatology. 54(1):173\u201384.","journal-title":"Hepatology."},{"issue":"1","key":"4856_CR7","first-page":"e3962","volume":"11","author":"N Patel","year":"2019","unstructured":"Patel, N, Benipal, B. (2019) Incidence of Cholangiocarcinoma in the USA from 2001 to 2015: A US Cancer Statistics Analysis of 50 States. Cureus. 11(1):e3962.","journal-title":"Cureus."},{"issue":"6","key":"4856_CR8","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.clinre.2020.03.024","volume":"44","author":"MM Gad","year":"2020","unstructured":"Gad, MM, Saad, AM, Faisaluddin, M, Gaman, MA, Ruhban, IA, Jazieh, KA, et al. (2020) Epidemiology of Cholangiocarcinoma; United States Incidence and Mortality Trends. Clin Res Hepatol Gastroenterol. 44(6):885\u201393.","journal-title":"Clin Res Hepatol Gastroenterol."},{"issue":"5","key":"4856_CR9","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/jnci\/djk068","volume":"99","author":"WR Matull","year":"2007","unstructured":"Matull, WR, Khan, SA, Pereira, SP. (2007) Re: Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst. 99(5):407; author reply\u2013\u20098.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"4856_CR10","doi-asserted-by":"publisher","first-page":"721","DOI":"10.2214\/ajr.175.3.1750721","volume":"175","author":"JW Lee","year":"2000","unstructured":"Lee, JW, Han, JK, Kim, TK, Kim, YH, Choi, BI, Han, MC, et al. (2000) CT features of intraductal intrahepatic cholangiocarcinoma. AJR Am J Roentgenol. 175(3):721\u20135.","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"4856_CR11","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","volume":"21","author":"SK Saha","year":"2016","unstructured":"Saha, SK, Zhu, AX, Fuchs, CS, Brooks, GA. (2016) Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise. Oncologist. 21(5):594\u20139.","journal-title":"Oncologist."},{"issue":"10","key":"4856_CR12","doi-asserted-by":"publisher","first-page":"e0186643","DOI":"10.1371\/journal.pone.0186643","volume":"12","author":"JL Petrick","year":"2017","unstructured":"Petrick, JL, Yang, B, Altekruse, SF, Van Dyke, AL, Koshiol, J, Graubard, BI, et al. (2017) Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: A population-based study in SEER-Medicare. PloS one. 12(10):e0186643.","journal-title":"PloS one."},{"issue":"12","key":"4856_CR13","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/jnci\/djj234","volume":"98","author":"TM Welzel","year":"2006","unstructured":"Welzel, TM, McGlynn, KA, Hsing, AW, O\u2019Brien, TR, Pfeiffer, RM. (2006) Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst. 98(12):873\u20135.","journal-title":"J Natl Cancer Inst."},{"issue":"3","key":"4856_CR14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1200\/JCO.2015.61.3778","volume":"34","author":"R Tao","year":"2016","unstructured":"Tao, R, Krishnan, S, Bhosale, PR, Javle, MM, Aloia, TA, Shroff, RT, et al. (2016) Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. J Clin Oncol. 34(3):219\u201326.","journal-title":"J Clin Oncol"},{"key":"4856_CR15","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1186\/s12885-015-1498-0","volume":"15","author":"A Stein","year":"2015","unstructured":"Stein, A, Arnold, D, Bridgewater, J, Goldstein, D, Jensen, LH, Klumpen, HJ, et al. (2015) Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. BMC cancer. 15:564.","journal-title":"BMC cancer"},{"issue":"1","key":"4856_CR16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jhep.2019.09.007","volume":"72","author":"O Clements","year":"2020","unstructured":"Clements, O, Eliahoo, J, Kim, JU, Taylor-Robinson, SD, Khan, SA. (2020) Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis. J Hepatol. 72(1):95\u2013103.","journal-title":"J Hepatol"},{"key":"4856_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00080","volume":"2","author":"A Jain","year":"2018","unstructured":"Jain, A, Borad, MJ, Kelley, RK, Wang, Y, Abdel-Wahab, R, Meric-Bernstam, F, et al. (2018) Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype. JCO Precis Oncol. 2:1\u201312.","journal-title":"JCO Precis Oncol"},{"issue":"Suppl 1","key":"4856_CR18","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/liv.14086","volume":"39","author":"A Forner","year":"2019","unstructured":"Forner, A, Vidili, G, Rengo, M, Bujanda, L, Ponz-Sarvise, M, Lamarca, A. (2019) Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int. 39 Suppl 1:98\u2013107.","journal-title":"Liver Int."},{"key":"4856_CR19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fsurg.2016.00014","volume":"3","author":"ST Orcutt","year":"2016","unstructured":"Orcutt, ST, Kobayashi, K, Sultenfuss, M, Hailey, BS, Sparks, A, Satpathy, B, et al. (2016) Portal Vein Embolization as an Oncosurgical Strategy Prior to Major Hepatic Resection: Anatomic, Surgical, and Technical Considerations. Frontiers in surgery. 3:14.","journal-title":"Frontiers in surgery"},{"issue":"2","key":"4856_CR20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.21037\/hbsn.2016.12.10","volume":"6","author":"K Fabrega-Foster","year":"2017","unstructured":"Fabrega-Foster, K, Ghasabeh, MA, Pawlik, TM, Kamel, IR. (2017) Multimodality imaging of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 6(2):67\u201378.","journal-title":"Hepatobiliary Surg Nutr."},{"issue":"1","key":"4856_CR21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1148\/radiol.2016151781","volume":"281","author":"J Lee","year":"2016","unstructured":"Lee, J, Kim, SH, Kang, TW, Song, KD, Choi, D, Jang, KT. (2016) Mass-forming Intrahepatic Cholangiocarcinoma: Diffusion-weighted Imaging as a Preoperative Prognostic Marker. Radiology. 281(1):119\u201328.","journal-title":"Radiology."},{"issue":"2","key":"4856_CR22","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3390\/curroncol29020061","volume":"29","author":"JD Kovac","year":"2022","unstructured":"Kovac, JD, Jankovic, A, Dikic-Rom, A, Grubor, N, Antic, A, Dugalic, V. (2022) Imaging Spectrum of Intrahepatic Mass-Forming Cholangiocarcinoma and Its Mimickers: How to Differentiate Them Using MRI. Curr Oncol. 29(2):698\u2013723.","journal-title":"Curr Oncol."},{"issue":"1","key":"4856_CR23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jhep.2019.01.038","volume":"71","author":"A Lamarca","year":"2019","unstructured":"Lamarca, A, Barriuso, J, Chander, A, McNamara, MG, Hubner, RA, D, OR, et al. (2019) (18)F-fluorodeoxyglucose positron emission tomography ((18)FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis. J Hepatol. 71(1):115\u201329.","journal-title":"J Hepatol."},{"key":"4856_CR24","first-page":"314","volume-title":"Pathology and Genetics of Tumours of the Digestive System","author":"LA Aaltonen","year":"2000","unstructured":"Aaltonen, LA, Hamilton, SR. (2000) Pathology and Genetics of Tumours of the Digestive System. 3rd ed. WHO Classification of Tumours: IARC Press; 314 p.","edition":"3"},{"issue":"11","key":"4856_CR25","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1001\/jamasurg.2014.1711","volume":"149","author":"K Lau","year":"2014","unstructured":"Lau, K, Salami, A, Barden, G, Khawja, S, Castillo, DL, Poppelaars, V, et al. (2014) The effect of a regional hepatopancreaticobiliary surgical program on clinical volume, quality of cancer care, and outcomes in the Veterans Affairs system. JAMA Surg. 149(11):1153\u201361.","journal-title":"JAMA Surg"},{"issue":"4","key":"4856_CR26","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1245\/s10434-021-10909-y","volume":"29","author":"J Ehab","year":"2022","unstructured":"Ehab, J, Powers, B, Kim, R, Haider, M, Utuama, O, Chin, A, et al. (2022) Integrating a Disease-Focused Tumor Board as a Delivery-of-Care Model to Expedite Treatment Initiation for Patients With Liver Malignancies. Ann Surg Oncol. 29(4):2371\u201380.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"4856_CR27","doi-asserted-by":"publisher","first-page":"e123-31","DOI":"10.3747\/co.20.1297","volume":"20","author":"J Zhang","year":"2013","unstructured":"Zhang, J, Mavros, MN, Cosgrove, D, Hirose, K, Herman, JM, Smallwood-Massey, S, et al. (2013) Impact of a single-day multidisciplinary clinic on the management of patients with liver tumours. Curr Oncol. 20(2):e123-31.","journal-title":"Curr Oncol."},{"issue":"4","key":"4856_CR28","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/S1072-7515(01)01016-X","volume":"193","author":"SM Weber","year":"2001","unstructured":"Weber, SM, Jarnagin, WR, Klimstra, D, DeMatteo, RP, Fong, Y, Blumgart, LH. (2001) Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg. 193(4):384\u201391.","journal-title":"J Am Coll Surg."},{"key":"4856_CR29","doi-asserted-by":"crossref","unstructured":"Beal, EW, Cloyd, JM, Pawlik, TM. (2020) Surgical Treatment of Intrahepatic Cholangiocarcinoma: Current and Emerging Principles. J Clin Med. 10(1).","DOI":"10.3390\/jcm10010104"},{"issue":"12","key":"4856_CR30","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/archsurg.2012.1962","volume":"147","author":"D Ribero","year":"2012","unstructured":"Ribero, D, Pinna, AD, Guglielmi, A, Ponti, A, Nuzzo, G, Giulini, SM, et al. (2012) Surgical Approach for Long-term Survival of Patients With Intrahepatic Cholangiocarcinoma: A Multi-institutional Analysis of 434 Patients. Arch Surg. 147(12):1107\u201313.","journal-title":"Arch Surg"},{"issue":"5","key":"4856_CR31","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1097\/SLA.0b013e318236c21d","volume":"254","author":"O Farges","year":"2011","unstructured":"Farges, O, Fuks, D, Boleslawski, E, Le Treut, YP, Castaing, D, Laurent, A, et al. (2011) Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma: a multicenter study by the AFC-IHCC-2009 study group. Ann Surg. 254(5):824\u201329; discussion 30.","journal-title":"Ann Surg."},{"key":"4856_CR32","doi-asserted-by":"crossref","unstructured":"Sinnamon, AJ, Luo, E, Xu, A, Zhu, S, Denbo, JW, Fleming, JB, et al. (2022) Clockwise Anterior-to-Posterior-Double Isolation (CAP-DI) Approach for Portal Lymphadenectomy in Biliary Tract Cancer: Technique, Yield, and Outcomes. Cancers (Basel). 14(23).","DOI":"10.3390\/cancers14235770"},{"issue":"4","key":"4856_CR33","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1245\/s10434-020-09478-3","volume":"28","author":"O Utuama","year":"2021","unstructured":"Utuama, O, Permuth, JB, Dagne, G, Sanchez-Anguiano, A, Alman, A, Kumar, A, et al. (2021) Neoadjuvant Chemotherapy for Intrahepatic Cholangiocarcinoma: A Propensity Score Survival Analysis Supporting Use in Patients with High-Risk Disease. Ann Surg Oncol. 28(4):1939\u201349.","journal-title":"Ann Surg Oncol"},{"issue":"Suppl 3","key":"4856_CR34","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1245\/s10434-021-10016-y","volume":"28","author":"JW Denbo","year":"2021","unstructured":"Denbo, JW, Kim, R, Anaya, DA. (2021) ASO Author Reflections: Evolving Treatment Paradigms for High-Risk Intrahepatic Cholangiocarcinoma: What Does The Future Hold? Ann Surg Oncol. 28(Suppl 3):854\u20135.","journal-title":"Ann Surg Oncol."},{"issue":"9","key":"4856_CR35","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1016\/j.ejso.2020.04.007","volume":"46","author":"S Conci","year":"2020","unstructured":"Conci, S, Vigano, L, Ercolani, G, Gonzalez, E, Ruzzenente, A, Isa, G, et al. (2020) Outcomes of vascular resection associated with curative intent hepatectomy for intrahepatic cholangiocarcinoma. Eur J Surg Oncol. 46(9):1727\u201333.","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"4856_CR36","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1245\/s10434-012-2808-2","volume":"20","author":"SM Ali","year":"2013","unstructured":"Ali, SM, Clark, CJ, Zaydfudim, VM, Que, FG, Nagorney, DM. (2013) Role of major vascular resection in patients with intrahepatic cholangiocarcinoma. Ann Surg Oncol. 20(6):2023\u20138.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"4856_CR37","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/jso.24633","volume":"116","author":"BN Reames","year":"2017","unstructured":"Reames, BN, Ejaz, A, Koerkamp, BG, Alexandrescu, S, Marques, HP, Aldrighetti, L, et al. (2017) Impact of major vascular resection on outcomes and survival in patients with intrahepatic cholangiocarcinoma: A multi-institutional analysis. J Surg Oncol. 116(2):133\u20139.","journal-title":"J Surg Oncol"},{"issue":"7","key":"4856_CR38","doi-asserted-by":"publisher","first-page":"694","DOI":"10.6004\/jnccn.2023.0035","volume":"21","author":"AB Benson","year":"2023","unstructured":"Benson, AB, D\u2019Angelica, MI, Abrams, T, Abbott, DE, Ahmed, A, Anaya, DA, et al. (2023) NCCN Guidelines(R) Insights: Biliary Tract Cancers, Version 2.2023. J Natl Compr Canc Netw. 21(7):694\u2013704.","journal-title":"J Natl Compr Canc Netw."},{"issue":"2","key":"4856_CR39","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.jhep.2019.11.020","volume":"72","author":"V Mazzaferro","year":"2020","unstructured":"Mazzaferro, V, Gorgen, A, Roayaie, S, Droz Dit Busset, M, Sapisochin, G. (2020) Liver resection and transplantation for intrahepatic cholangiocarcinoma. J Hepatol. 72(2):364\u201377.","journal-title":"J Hepatol."},{"issue":"3","key":"4856_CR40","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.21037\/jgo-21-868","volume":"13","author":"AJ Sinnamon","year":"2022","unstructured":"Sinnamon, AJ, Wood, AC, Satyadi, MA, Levitt, CV, Hardy, O, Haider, M, et al. (2022) Anatomic patterns of recurrence in biliary tract cancers: does primary tumor site matter? J Gastrointest Oncol. 13(3):1413\u201322.","journal-title":"J Gastrointest Oncol"},{"issue":"5","key":"4856_CR41","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose, JN, Fox, RP, Palmer, DH, Malik, HZ, Prasad, R, Mirza, D, et al. (2019) Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. The Lancet Oncology. 20(5):663\u201373.","journal-title":"The Lancet Oncology."},{"issue":"10372","key":"4856_CR42","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0140-6736(22)02038-4","volume":"401","author":"K Nakachi","year":"2023","unstructured":"Nakachi, K, Ikeda, M, Konishi, M, Nomura, S, Katayama, H, Kataoka, T, et al. (2023) Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 401(10372):195\u2013203.","journal-title":"Lancet."},{"issue":"8","key":"4856_CR43","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1200\/JCO.18.00050","volume":"37","author":"J Edeline","year":"2019","unstructured":"Edeline, J, Benabdelghani, M, Bertaut, A, Watelet, J, Hammel, P, Joly, JP, et al. (2019) Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study. J Clin Oncol. 37(8):658\u201367.","journal-title":"J Clin Oncol."},{"issue":"14","key":"4856_CR44","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle, J, Wasan, H, Palmer, DH, Cunningham, D, Anthoney, A, Maraveyas, A, et al. (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. The New England journal of medicine. 362(14):1273\u201381.","journal-title":"The New England journal of medicine"},{"issue":"8","key":"4856_CR45","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh, DY, Ruth He, A, Qin, S, Chen, LT, Okusaka, T, Vogel, A, et al. (2022) Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid. 1(8):EVIDoa2200015.","journal-title":"NEJM Evid."},{"issue":"10391","key":"4856_CR46","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley, RK, Ueno, M, Yoo, C, Finn, RS, Furuse, J, Ren, Z, et al. (2023) Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 401(10391):1853\u201365.","journal-title":"Lancet"},{"issue":"5","key":"4856_CR47","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","volume":"22","author":"A Lamarca","year":"2021","unstructured":"Lamarca, A, Palmer, DH, Wasan, HS, Ross, PJ, Ma, YT, Arora, A, et al. (2021) Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. The Lancet Oncology. 22(5):690\u2013701.","journal-title":"The Lancet Oncology."},{"issue":"1","key":"4856_CR48","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/jhbp.1219","volume":"30","author":"T Ioka","year":"2023","unstructured":"Ioka, T, Kanai, M, Kobayashi, S, Sakai, D, Eguchi, H, Baba, H, et al. (2023) Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA). J Hepatobiliary Pancreat Sci. 30(1):102\u201310.","journal-title":"J Hepatobiliary Pancreat Sci."},{"issue":"24","key":"4856_CR49","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1200\/JCO.2014.60.2219","volume":"33","author":"E Ben-Josef","year":"2015","unstructured":"Ben-Josef, E, Guthrie, KA, El-Khoueiry, AB, Corless, CL, Zalupski, MM, Lowy, AM, et al. (2015) SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. J Clin Oncol. 33(24):2617\u201322.","journal-title":"J Clin Oncol"},{"issue":"4","key":"4856_CR50","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.3892\/or.2013.2290","volume":"29","author":"R Dhanasekaran","year":"2013","unstructured":"Dhanasekaran, R, Hemming, AW, Zendejas, I, George, T, Nelson, DR, Soldevila-Pico, C, et al. (2013) Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma. Oncol Rep. 29(4):1259\u201367.","journal-title":"Oncol Rep."},{"key":"4856_CR51","doi-asserted-by":"publisher","first-page":"604387","DOI":"10.3389\/fonc.2020.604387","volume":"10","author":"E Gkika","year":"2020","unstructured":"Gkika, E, Hawkins, MA, Grosu, AL, Brunner, TB. (2020) The Evolving Role of Radiation Therapy in the Treatment of Biliary Tract Cancer. Front Oncol. 10:604387.","journal-title":"Front Oncol"},{"issue":"7","key":"4856_CR52","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1245\/s10434-014-4275-4","volume":"22","author":"MD Sur","year":"2015","unstructured":"Sur, MD, In, H, Sharpe, SM, Baker, MS, Weichselbaum, RR, Talamonti, MS, et al. (2015) Defining the Benefit of Adjuvant Therapy Following Resection for Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 22(7):2209\u201317.","journal-title":"Ann Surg Oncol."},{"issue":"5","key":"4856_CR53","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.ijrobp.2008.03.018","volume":"72","author":"ET Shinohara","year":"2008","unstructured":"Shinohara, ET, Mitra, N, Guo, M, Metz, JM. (2008) Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma. International journal of radiation oncology, biology, physics. 72(5):1495\u2013501.","journal-title":"International journal of radiation oncology, biology, physics."},{"issue":"9","key":"4856_CR54","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.jvir.2023.05.026","volume":"34","author":"B Kis","year":"2023","unstructured":"Kis, B, Shridhar, R, Mhaskar, R, Gyano, M, Frakes, JM, El-Haddad, G, et al. (2023) Radioembolization with Yttrium-90 Glass Microspheres as a First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma-A Prospective Feasibility Study. J Vasc Interv Radiol. 34(9):1547\u201355.","journal-title":"J Vasc Interv Radiol"},{"issue":"5","key":"4856_CR55","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.jceh.2022.03.008","volume":"12","author":"P Kumar","year":"2022","unstructured":"Kumar, P, Mhaskar, R, Kim, R, Anaya, D, Frakes, J, Hoffe, S, et al. (2022) Unresectable Intrahepatic Cholangiocarcinoma Treated with Radiation Segmentectomy\/Lobectomy Using Yttrium 90-labeled Glass Microspheres. J Clin Exp Hepatol. 12(5):1259\u201363.","journal-title":"J Clin Exp Hepatol"},{"key":"4856_CR56","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1186\/1471-2407-10-492","volume":"10","author":"YX Chen","year":"2010","unstructured":"Chen, YX, Zeng, ZC, Tang, ZY, Fan, J, Zhou, J, Jiang, W, et al. (2010) Determining the role of external beam radiotherapy in unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 84 patients. BMC cancer. 10:492.","journal-title":"BMC cancer"},{"issue":"3","key":"4856_CR57","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/COC.0000000000000646","volume":"43","author":"SP Hung","year":"2020","unstructured":"Hung, SP, Huang, BS, Hsieh, CE, Lee, CH, Tsang, NM, Chang, JT, et al. (2020) Clinical Outcomes of Patients With Unresectable Cholangiocarcinoma Treated With Proton Beam Therapy. Am J Clin Oncol. 43(3):180\u20136.","journal-title":"Am J Clin Oncol"}],"container-title":["Abdominal Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-025-04856-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00261-025-04856-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-025-04856-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T10:01:19Z","timestamp":1757152879000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00261-025-04856-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":57,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["4856"],"URL":"https:\/\/doi.org\/10.1007\/s00261-025-04856-5","relation":{},"ISSN":["2366-0058"],"issn-type":[{"value":"2366-0058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"assertion":[{"value":"19 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}